Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial
Schouten, Aniek E.M.; Hiensch, Anouk E.; Frederix, Geert W.J.; Monninkhof, Evelyn M.; Schmidt, Martina E.; Clauss, Dorothea; Gunasekara, Nadira; Belloso, Jon; Trevaskis, Mark; Rundqvist, Helene; Wiskemann, Joachim; Müller, Jana; Sweegers, Maike G.; Fremd, Carlo; Altena, Renske; Bijlsma, Rhodé M.; Sonke, Gabe; Lahuerta, Ainhara; Mann, G. Bruce; Francis, Prudence A.; Richardson, Gary; Malter, Wolfram; Kufel-Grabowska, Joanna; Van Der Wall, Elsken; Aaronson, Neil K.; Senkus, Elzbieta; Urruticoechea, Ander; Zopf, Eva M.; Bloch, Wilhelm; Stuiver, Martijn M.; Wengstrom, Yvonne; Steindorf, Karen; Van Der Meulen, Miriam P.; May, Anne M.
(2025) Journal of Clinical Oncology, volume 43, issue 11, pp. 1325 - 1337
(Article)
Abstract
PURPOSETo evaluate the cost utility of a 9-month supervised exercise program for patients with metastatic breast cancer (mBC), compared with control (usual care, supplemented with general activity advice and an activity tracker). Evidence on the cost-effectiveness of exercise for patients with mBC is essential for implementation in clinical practice and
... read more
is currently lacking.METHODSA cost-utility analysis was performed alongside the multinational PREFERABLE-EFFECT randomized controlled trial, conducted in 8 centers across Europe and Australia. Patients with mBC (N = 357) were randomly assigned to either a 9-month, twice-weekly, supervised exercise group (EG) or control group (CG). Costs of the exercise program were calculated through a bottom-up approach. Other health care resource use, productivity losses, and quality of life were collected using country-adapted, self-reported questionnaires. Analyses were conducted from a societal perspective with a time horizon of 9 months. Costs were collected and reported in 2021 Euros (1 = $1.18 US dollars).RESULTSCompared with the CG, EG resulted in a quality-adjusted life-year (QALY) gain of 0.013 (95% CI, -0.02 to 0.05) over a 9-month period. The mean costs of the exercise program were 1,696 per patient with one-on-one supervision (scenario 1) and 609 with one-on-four supervision (scenario 2). These costs were offset by savings in health care and productivity costs, resulting in mean total cost differences of -163 (scenario 1) and -1,249 (scenario 2) in favor of EG. The probability of supervised exercise being cost-effective was 65% in scenario 1 and 91% in scenario 2 at a willingness-to-pay threshold of 20,000 per QALY.CONCLUSIONExercise for patients with mBC increases quality of life, decreases costs, and is likely to be cost-effective. Group-based supervision is expected to have even higher cost-savings. Our positive findings can inform reimbursement of supervised exercise interventions for patients with mBC.
show less
Download/Full Text
Keywords: Oncology, Cancer Research
ISSN: 0732-183X
Publisher: Lippincott Williams & Wilkins
Note: Publisher Copyright: © American Society of Clinical Oncology.
(Peer reviewed)